This database contains 41 studies, archived under the term: "Hospital Inpatient Care"
Click here to filter this large number of results.
Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial
Culo, Sandi,
Mulsant, Benoit H.,
Rosen, Jules,
Mazumdar, Sati,
Blakesley, Richard E.,
Houck, Patricia R.,
Pollock, Bruce G.
Sensitivity to psychotropic medications presents a therapeutic challenge when treating neuropsychiatric symptoms in patients with dementia with Lewy bodies (DLB). We compared under randomized, double-blinded conditions the tolerability and efficacy of citalopram and risperidone in the treatment of behavioral and psychotic symptoms in patients with DLB and Alzheimer disease (AD). Thirty-one participants with DLB and […]
A new combined strategy to implement a community occupational therapy intervention: designing a cluster randomized controlled trial
Döpp, Carola M. E.,
Graff, Maud J. L.,
Teerenstra, Steven,
Adang, Eddy,
Nijhuis-van der Sanden, Ria W. G.,
Olderikkert, Marcel G. M.,
Vernooij-Dassen, Myrra J. F. J.
Background: Even effective interventions for people with dementia and their caregivers require specific implementation efforts. A pilot study showed that the highly effective community occupational therapy in dementia (COTiD) program was not implemented optimally due to various barriers. To decrease these barriers and make implementation of the program more effective a combined implementation (CI) strategy […]
Effect of an antioxidant drink on homocysteine levels in Alzheimer’s patients
Morillas-Ruiz, J. M.,
Rubio-Perez, J. M.,
Albaladejo, M. D.,
Zafrilla, P.,
Parra, S.,
Vidal-Guevara, M. L.
Background: A large body of evidence supports a role of oxidative stress in Alzheimer disease (AD) and in cerebrovascular disease. Blood levels of homocysteine may be increased in AD and hyperhomocysteinemia may contribute to disease pathophysiology by vascular and direct neurotoxic mechanisms. Even in the absence of vitamin deficiency, plasma total homocysteine (tHcy) concentration may […]
Evaluation of a Medical and Mental Health Unit compared with standard care for older people whose emergency admission to an acute general hospital is complicated by concurrent ‘confusion’: a controlled clinical trial. Acronym: TEAM: Trial of an Elderly Acute care Medical and mental health unit
Harwood, Rowan H.,
Goldberg, Sarah E.,
Whittamore, Kathy H.,
Russell, Catherine,
Gladman, John Rf,
Jones, Rob G.,
Porock, Davina,
Lewis, Sarah A.,
Bradshaw, Lucy E.,
Elliot, Rachel A.
Background: Patients with delirium and dementia admitted to general hospitals have poor outcomes, and their carers report poor experiences. We developed an acute geriatric medical ward into a specialist Medical and Mental Health Unit over an eighteen month period. Additional specialist mental health staff were employed, other staff were trained in the ‘person-centred’ dementia care […]
Inhaled sevoflurane may promote progression of amnestic mild cognitive impairment: a prospective, randomized parallel-group study
Liu, Yongzhe,
Pan, Ningling,
Ma, Yaqun,
Zhang, Shengshuo,
Guo, Wenzhi,
Li, Haihong,
Zhou, Jingli,
Liu, Gang,
Gao, Minglong
Background: Amnestic mild cognitive impairment (aMCI) is thought to be a transitional stage between normal aging and the development of Alzheimer’s disease (AD). Recent studies have suggested that the inhalational anesthetic isoflurane can induce caspase activation and apoptosis, increase aggregates of β-amyloid (Aβ) levels, and enhance Aβ aggregation. The aim of this study was to […]
Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms
Dombrovski, Alexandre Y.,
Mulsant, Benoit H.,
Ferrell, Robert E.,
Lotrich, Francis E.,
Rosen, Jules I.,
Wallace, Meredith,
Houck, Patricia R.,
Mazumdar, Sati,
Pollock, Bruce G.
The risk/benefit ratio of pharmacotherapy for behavioral symptoms of dementia is questionable: second-generation antipsychotics are poorly tolerated, and the efficacy of alternative treatments, for example, selective serotonin-reuptake inhibitors (SSRIs), is uncertain. Biomarkers of treatment response may improve this risk/benefit ratio. The length polymorphism of the serotonin transporter promoter gene (5-HTTLPR/SLC6A4) may moderate tolerability of SSRIs […]